Trial by CCN2: a standardized test for fibroproliferative disease?

A major issue concerning clinical trials is the availability of standardized assays to evaluate drug efficacy. Ideally, such assays should test the effect of a putative drug on the expression of a biomarker in biological fluids. In a recent study by Kuiper et al. (PLOS One, 3(7): e2675). The relativ...

Descripción completa

Detalles Bibliográficos
Autor principal: Leask, Andrew
Formato: Texto
Lenguaje:English
Publicado: Springer Netherlands 2009
Materias:
Bits and Bytes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686749/
https://www.ncbi.nlm.nih.gov/pubmed/19266315
http://dx.doi.org/10.1007/s12079-009-0041-y
Descripción
Sumario:A major issue concerning clinical trials is the availability of standardized assays to evaluate drug efficacy. Ideally, such assays should test the effect of a putative drug on the expression of a biomarker in biological fluids. In a recent study by Kuiper et al. (PLOS One, 3(7): e2675). The relative levels of vascular endothelial growth factor (VEGF) and CCN2 (connective tissue growth factor [CTGF]) were examined in proliferative diabetic retinopathy (PDR). This paper is the subject of this commentary.

Ejemplares similares